



## Model List of Essential Medicines



### Medicines for COVID-19 [General information](#)

Section

Medicines for COVID-19

- Refer to WHO living guidelines

Indications

[COVID-19](#)



### Abacavir [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 300 mg tablet (as sulfate)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



### Abacavir + dolutegravir + lamivudine [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid > tablet: 60 mg (as sulfate) + 5 mg + 30 mg (dispersible, scored)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



### Abacavir + lamivudine [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



### Abacavir + lamivudine + lopinavir + ritonavir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

[unspecified](#)



#### **Aciclovir [General information](#)**

Section

Antitherpes medicines

- Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)
- Oral > Liquid: 200 mg per 5 mL
- Oral > Solid: 200 mg tablet
- Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)

Indications

[Herpes simplex infections Zoster Varicella](#)



#### **Albendazole [General information](#)**

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 400 mg (chewable, scored)

Indications

[Trichuriasis Echinococcosis Cysticercosis Enterobiasis Hookworm diseases Ascariasis](#)

Section

Cysticidal medicines

- Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)

Indications

[Other specified echinococcosis Cysticercosis of central nervous system](#)

Section

Antifilarials

- Oral > Solid > tablet: 400 mg (chewable, scored)

Indications

[Lymphatic filariasis](#)



#### **Amikacin [General information](#)**

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 50 mg per mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

**First choice**

[Neutropenia \(high-risk\)](#) co-prescribed with [cefotaxime Inflammatory and other diseases of prostate \(severe\)](#) co-prescribed with [cefotaxime Acute pyelonephritis \(severe\)](#) co-prescribed with [ceftriaxone Inflammatory and other diseases of prostate \(severe\)](#) co-prescribed with [ceftriaxone Acute pyelonephritis \(severe\)](#)

Section

Antituberculosis medicines

- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



#### **Amodiaquine [General information](#)**

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)

Indications

[Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax](#)



#### **Amodiaquine - sulfadoxine + pyrimethamine [General information](#)**

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid > dispersible tablet: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 153

mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package; 75 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 150 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package

Indications

[Malaria](#)



#### **Amoxicillin [General information](#)**

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
- Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
- Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)

Indications

**First choice**

[Acute pharyngitis](#) [Periapical abscess without sinus](#) [Acute sinusitis](#) [Acute otitis media](#) [Chronic obstructive pulmonary disease with acute exacerbation](#) [Acute malnutrition in infants, children or adolescents \(uncomplicated\) \[children\]](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) [Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribed with [gentamicin](#) [Sepsis without septic shock](#)

**Second choice**

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#) [Infectious cystitis](#)



#### **Amoxicillin + clavulanic acid [General information](#)**

Section

Access group antibiotics

- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

**First choice**

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Infectious cystitis](#) [Acute sinusitis](#) [Neutropenia \(low-risk\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Bacterial cellulitis, erysipelas or lymphangitis](#) [Chronic obstructive pulmonary disease with acute exacerbation](#) [Peritonitis \(mild-moderate\)](#) [Peritoneal abscess \(mild-moderate\)](#)

**Second choice**

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Osteomyelitis or osteitis](#) [Bacterial infection of joint](#) [Other specified prophylactic measures](#) [Acute otitis media](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Antituberculosis medicines

- Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

### **Amphotericin B [General information](#)**

Section

Antifungal medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

Indications

[Candidosis](#) [Blastomycosis](#) [Cryptococcosis](#) [Coccidioidomycosis](#) [Histoplasmosis](#) [Sporotrichosis](#) [Aspergillosis](#)

Section

Antileishmaniasis medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

Indications

[Visceral leishmaniasis](#)

### **Ampicillin [General information](#)**

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
- Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

**First choice**

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) [Peritonitis \(mild-moderate\)](#) [Peritonitis \(severe\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritoneal abscess \(severe\)](#) co-prescribed with [gentamicin](#) [Sepsis without septic shock](#)

**Second choice**

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#)

### **Anidulafungin [General information](#)**

Section

Antifungal medicines

Indications

Therapeutic equivalent to [micafungin](#) for [Systemic or invasive candidosis](#)

### **Ansuvimab [General information](#)**

Section

Medicines for Ebola virus disease

- Parenteral > General injections > IV: 400 mg powder for injection

Indications

[Ebola virus disease](#)

### **Arpraziquantel [General information](#)**

Section

Antischistosomes and other antitrematode medicines

- Oral > Solid > dispersible tablet: 150 mg

Indications

Therapeutic equivalent to [praziquantel](#) for [Schistosomiasis](#)

### **Artemether [General information](#)**

Section

Antimalarial medicines > Medicines for curative treatment

- Parenteral > General injections > IM: 20 mg per mL in 1 mL ampoule (oily injection); 40 mg per mL in 1 mL

ampoule (oily injection)

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)

**Artemether + lumefantrine** [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > dispersible tablet: 20 mg + 120 mg
- Oral > Solid > tablet: 20 mg + 120 mg

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)

**Artesunate** [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Parenteral > General injections > IV: 60 mg in vial powder for injection; 30 mg in vial powder for injection; 120 mg in vial powder for injection
- Local > Rectal > Other: 100 mg capsules

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)

**Artesunate + amodiaquine** [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg
- Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg tablet

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)

**Artesunate + mefloquine** [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 25 mg + 50 mg (as hydrochloride); 100 mg + 200 mg (as hydrochloride)

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)

**Artesunate + pyronaridine** [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 60 mg + 180 mg (tetrphosphate)
- Oral > Solid > granules: 20 mg + 60 mg (tetrphosphate)

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)

**Artesunate - sulfadoxine + pyrimethamine** [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 50 mg [3] + 500 mg + 25 mg [1] in copackage (scored)

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)

**Atazanavir** [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

**Atazanavir + ritonavir [General information](#)**

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

**Atoltivimab + maftivimab + odesivimab [General information](#)**

Section

Medicines for Ebola virus disease

- Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial

Indications

[Ebola virus disease](#)

**Azithromycin [General information](#)**

Section

Watch group antibiotics

- Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

**First choice**

[Trachoma Cholera Cholera \[children\] Paratyphoid fever Chlamydia trachomatis Typhoid fever Yaws](#) co-prescribed with [ceftriaxone Gonococcal infection](#)

**Second choice**

[Infectious gastroenteritis or colitis without specification of infectious agent](#) co-prescribed with [cefixime Gonococcal infection](#)

**Aztreonam [General information](#)**

Section

Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

[Other specified bacterial diseases](#)

**Bedaquiline [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid > tablet: 100 mg tablet; 20 mg tablet

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

**Benzathine benzylpenicillin [General information](#)**

Section

Access group antibiotics

- Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection

Indications

**First choice**

[Congenital syphilis \[children\] Syphilis](#)

Other indications

[Bacterial infection of unspecified site](#)

**Benznidazole [General information](#)**

Section

American trypanosomiasis

- Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg

Indications

[Chagas disease](#)



**Benzylpenicillin [General information](#)**

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)

Indications

**First choice**

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Congenital syphilis \[children\]](#) [Syphilis](#)  
[Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [gentamicin](#)  
[Sepsis without septic shock](#)

**Second choice**

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#)



**Capreomycin [General information](#)**

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



**Caspofungin [General information](#)**

Section

Antifungal medicines

Indications

Therapeutic equivalent to [micafungin](#) for [Systemic or invasive candidosis](#)



**Cefalexin [General information](#)**

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid: 250 mg (as monohydrate)
- Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
- Oral > Solid > dispersible tablet: 125 mg; 250 mg

Indications

**First choice**

[Bacterial cellulitis, erysipelas or lymphangitis](#)

**Second choice**

[Chronic obstructive pulmonary disease with acute exacerbation](#) [Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)



**Cefazolin [General information](#)**

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

Indications

**First choice**

[Other specified prophylactic measures](#) [Other specified prophylactic measures](#)

**Second choice**

[Bacterial infection of joint Osteomyelitis or osteitis](#)

Other indications

[Surgical site infection](#)

**Cefepime** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

Indications

[Other specified bacterial diseases](#)

**Cefiderocol** [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)

**Cefixime** [General information](#)

Section

Watch group antibiotics

- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

Indications

**Second choice**

[Infectious gastroenteritis or colitis without specification of infectious agent](#) [Gonococcal infection](#)

**Cefotaxime** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

**First choice**

[Bacterial meningitis](#) [Inflammatory and other diseases of prostate \(severe\)](#) [Acute pyelonephritis \(severe\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritoneal abscess \(severe\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Peritonitis \(mild-moderate\)](#) [Peritonitis \(severe\)](#)

**Second choice**

[Inflammatory and other diseases of prostate \(mild to moderate\)](#) [Acute pyelonephritis \(mild to moderate\)](#) [Sepsis without septic shock](#) [Bacterial infection of joint Osteomyelitis or osteitis](#)

Other indications

[Bacterial infection of unspecified site](#)

### **Ceftaroline [General information](#)**

#### Section

Reserve group antibiotics

- Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection

Indications

[Other specified bacterial diseases](#)



### **Ceftazidime [General information](#)**

#### Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

Indications

**First choice**

[Endophthalmitis](#)

Other indications

[Pseudomonas aeruginosa resistant to other antibiotic](#)



### **Ceftazidime + avibactam [General information](#)**

#### Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales](#)



### **Ceftolozane + tazobactam [General information](#)**

#### Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g + 0.5 g powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#)



### **Ceftriaxone [General information](#)**

#### Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

**First choice**

[Other specified pneumonia \(Hospital-acquired pneumonia\) Inflammatory and other diseases of prostate \(severe\) Bacterial meningitis Acute pyelonephritis \(severe\) Paratyphoid fever Gonococcal infection Typhoid fever Peritonitis \(mild-moderate\) Peritonitis \(severe\) Peritoneal abscess \(mild-moderate\) Peritoneal abscess \(severe\) Endophthalmitis Bacterial pneumonia \(Community-acquired pneumonia - severe\) Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\] co-prescribed with metronidazole Necrotising fasciitis](#)

**Second choice**

[Inflammatory and other diseases of prostate \(mild to moderate\) Acute pyelonephritis \(mild to moderate\) Bacterial](#)

[infection of joint Sepsis without septic shock Osteomyelitis or osteitis Infectious gastroenteritis or colitis without specification of infectious agent](#)

Other indications

[Bacterial infection of unspecified site](#)

### **Cefuroxime [General information](#)**

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

**Second choice**

[Other specified prophylactic measures](#)

### **Chloramphenicol [General information](#)**

Section

Access group antibiotics

- Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
- Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
- Oral > Liquid: 150 mg per 5 mL (as palmitate)
- Oral > Solid: 250 mg capsule

Indications

**Second choice**

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#)

### **Chloroquine [General information](#)**

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate)

Indications

[Malaria due to Plasmodium falciparum Malaria due to Plasmodium ovale Malaria due to Plasmodium malariae](#)

[Malaria due to Plasmodium vivax](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)
- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)
- Oral > Liquid: 50 mg per 5 mL (base)
- Oral > Solid > tablet: 150 mg (base)

Indications

[Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax](#)

Section

Antimalarial medicines > Medicines for chemoprophylaxis in travellers

- Oral > Liquid: 50 mg per 5 mL (base)
- Oral > Solid > tablet: 150 mg (base)

Indications

[Malaria due to Plasmodium vivax](#)

### **Ciprofloxacin [General information](#)**

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 mg per mL (as hyclate)
- Oral > Liquid: 250 mg per 5 mL (anhydrous)
- Oral > Solid: 250 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

Indications

**First choice**

[Acute pyelonephritis \(mild to moderate\)](#) [Infectious gastroenteritis or colitis without specification of infectious agent](#) [Paratyphoid fever](#) [Typhoid fever](#) [Neutropenia \(low-risk\)](#) [Inflammatory and other diseases of prostate \(mild to moderate\)](#)

**Second choice**

[Cholera](#) [Cholera \[children\]](#) [Peritonitis \(mild-moderate\)](#) [Peritoneal abscess \(mild-moderate\)](#)

Other indications

[Bacterial infection of unspecified site](#)

**Clarithromycin** [General information](#)

Section

Watch group antibiotics

- Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
- Oral > Solid > dosage form: 500 mg; 250 mg
- Oral > Solid > dosage form: 500 mg

Indications

**First choice**

co-prescribed with [cefotaxime](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) co-prescribed with [ceftriaxone](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

**Second choice**

[Acute pharyngitis](#) co-prescribed with [amoxicillin + clavulanic acid](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

Other indications

[Helicobacter pylori associated gastric ulcer](#)

**Clindamycin** [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride) capsule
- Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
- Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
- Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride)

Indications

**First choice**

[Necrotising fasciitis](#)

**Second choice**

[Bacterial infection of joint](#) [Osteomyelitis or osteitis](#)

Other indications

[Bacterial infection of unspecified site](#)

**Clofazimine** [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Section

Antileprosy medicines

- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

[Leprosy](#)

**Clotrimazole [General information](#)**

Section

Antifungal medicines

- Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet

Indications

[Vulvovaginal candidosis](#)

**Cloxacillin [General information](#)**

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
- Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
- Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)

Indications

**First choice**

[Osteomyelitis or osteitis Bacterial infection of joint Bacterial cellulitis, erysipelas or lymphangitis](#)

**Second choice**

[Sepsis without septic shock](#)

Other indications

[Bacterial infection of unspecified site](#)

**Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate [General information](#)**

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

**Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide [General information](#)**

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

**Colistin (injection) [General information](#)**

Section

Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium)
- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium) (equivalent to 34 mg colistin base activity)

Indications

[Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales](#)

**Cycloserine [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid > dosage form: 250 mg; 125 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

**Daclatasvir [General information](#)**

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 30 mg (as dihydrochloride); 60 mg (as dihydrochloride)

Indications

[Chronic hepatitis C](#)

**Daclatasvir + sofosbuvir [General information](#)**

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg

Indications

[Chronic hepatitis C](#)

**Dapsone [General information](#)**

Section

Antileprosy medicines

- Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet

Indications

[Leprosy](#)

**Daptomycin [General information](#)**

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection

Indications

[Other specified bacterial diseases](#)

**Darunavir [General information](#)**

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

**Dasabuvir [General information](#)**

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 250 mg tablet

Indications

[Chronic hepatitis C](#)

**Delafloxacin [General information](#)**

Section

Watch group antibiotics

- Parenteral > General injections > IV: 300 mg lyophilized powder for injection
- Oral > Solid: 450 mg

Indications

[Methicillin resistant Staphylococcus aureus](#)

**Delamanid [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 25 mg
- Oral > Solid > tablet: 50 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



**Dicloxacillin** [General information](#)

Section

Access group antibiotics

Indications

**First choice**

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

**Second choice**

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)



**Didanosine** [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
- Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



**Diethylcarbamazine** [General information](#)

Section

Antifilarials

- Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)

Indications

[Lymphatic filariasis](#)



**Dihydroartemisinin + piperaquine** [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > dispersible tablet: 20 mg + 160 mg (phosphate); 40 mg + 320 mg (phosphate)
- Oral > Solid > tablet: 40 mg + 320 mg (phosphate); 20 mg + 160 mg (phosphate); 60 mg + 480 (phosphate); 80 mg + 640 mg (phosphate)

Indications

[Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax](#)



**Diloxanide** [General information](#)

Section

Antiamoebic and anti giardiasis medicines

- Oral > Solid: 500 mg (furoate)

Indications

[Amoebiasis](#)



**Dolutegravir** [General information](#)

Section

Antiretrovirals > Integrase inhibitors

- Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



#### **Dolutegravir + lamivudine + tenofovir [General information](#)**

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



#### **Doxycycline [General information](#)**

Section

Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
- Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
- Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
- Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
- Oral > Solid > dosage form: 100 mg (as hyclate)

Indications

**First choice**

[Cholera Chlamydia trachomatis](#)

**Second choice**

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\) Cholera \[children\] Chronic obstructive pulmonary disease with acute exacerbation](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Antimalarial medicines > Medicines for chemoprophylaxis in travellers

- Oral > Liquid: 50 mg per 5 mL (calcium); 25 mg per 5 mL (monohydrate) powder for oral liquid
- Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
- Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)

Indications

[Malaria due to Plasmodium falciparum](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)

Indications

[Malaria due to Plasmodium falciparum](#)

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid: 100 mg (hydrochloride or hyclate)

Indications

[Malaria due to Plasmodium falciparum](#)



#### **Efavirenz [General information](#)**

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

- Oral > Solid: 600 mg tablet

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



#### **Efavirenz + emtricitabine + tenofovir [General information](#)**

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

#### **Efavirenz + lamivudine + tenofovir [General information](#)**

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#) Therapeutic equivalent to [efavirenz + emtricitabine + tenofovir](#) for [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

#### **Eflornithine [General information](#)**

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

- Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)

Indications

[Gambiense trypanosomiasis](#)

#### **Elbasvir + grazoprevir [General information](#)**

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 50 mg + 100 mg

Indications

[Chronic hepatitis C](#)

#### **Emtricitabine [General information](#)**

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 10 mg per mL
- Oral > Solid: 200 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

#### **Emtricitabine + rilpivirine + tenofovir alafenamide [General information](#)**

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 25 mg + 25 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

#### **Emtricitabine + rilpivirine + tenofovir disoproxil fumarate [General information](#)**

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

#### **Emtricitabine + tenofovir [General information](#)**

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)  
[Contact with or exposure to human immunodeficiency virus](#)

#### **Emtricitabine + tenofovir alafenamide** [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

#### **Entecavir** [General information](#)

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 0.05 mg per mL
- Oral > Solid: 0.5 mg; 1 mg

Indications

[Chronic hepatitis B](#)

#### **Eravacycline** [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg lyophilized powder for injection

Indications

[Carbapenem resistant Enterobacterales](#)

#### **Erythromycin** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
- Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
- Oral > Solid: 250 mg (as stearate or ethylsuccinate)

Indications

**Second choice**

Therapeutic equivalent to [clarithromycin](#) for [Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)

#### **Ethambutol** [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)

Indications

[Other specified tuberculosis](#)  
[Tuberculosis](#)

#### **Ethambutol + isoniazid** [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 400 mg + 150 mg tablet

Indications

[Tuberculosis](#)

#### **Ethambutol + isoniazid + pyrazinamide + rifampicin** [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

Indications

[Tuberculosis](#)



**Ethambutol + isoniazid + rifampicin [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid: 275 mg + 75 mg + 150 mg tablet

Indications

[Tuberculosis](#)



**Ethionamide [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 125 mg
- Oral > Solid > tablet: 250 mg

Indications

[Tuberculous meningitis Multi-drug resistant Mycobacterium tuberculosis](#)



**Fexinidazole [General information](#)**

Section

Medicines for the treatment of 1st stage African trypanosomiasis

- Oral > Solid > tablet: 600 mg
- Oral > Solid: 600 mg

Indications

[Rhodesiense trypanosomiasis Gambiense trypanosomiasis](#)

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

- Oral > Solid > tablet: 600 mg
- Oral > Solid: 600 mg

Indications

[Rhodesiense trypanosomiasis Gambiense trypanosomiasis](#)



**Fifth generation cephalosporins [General information](#)**

Section

Reserve group antibiotics

- .

Indications

[Other specified bacterial diseases](#)



**Flomoxef [General information](#)**

Section

Watch group antibiotics

- Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection

Indications

[Other specified other antibiotic resistant Enterobacterales](#)



**Flucloxacillin [General information](#)**

Section

Access group antibiotics

Indications

**First choice**

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

**Second choice**

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

#### **Fluconazole** [General information](#)

Section

Antifungal medicines

- Parenteral > General injections > IV: 2 mg per mL in vial
- Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid
- Oral > Solid > capsule: 50 mg

Indications

[Cryptococcosis](#) [Candidosis](#)

#### **Flucytosine** [General information](#)

Section

Antifungal medicines

- Parenteral > General injections > IV: 2.5 g per 250 mL infusion
- Oral > Solid: 250 mg capsule

Indications

[Cryptococcosis](#)

#### **Fosfomycin (injection)** [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

Indications

[Other specified bacterial diseases](#) [Carbapenem resistant Acinetobacter baumannii](#) [Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)

#### **Fourth generation cephalosporins** [General information](#)

Section

Watch group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

#### **Gatifloxacin** [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 200 mg; 400 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

#### **Gentamicin** [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Indications

**First choice**

[Neonatal meningitis](#) [Sepsis without septic shock](#) [Sepsis without septic shock](#) [Sepsis without septic shock](#) co-prescribed with [amoxicillin Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribed with [ampicillin Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [ampicillin Peritonitis \(mild-moderate\)](#) co-prescribed with [ampicillin Peritonitis \(severe\)](#) co-prescribed with [ampicillin Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [ampicillin Peritoneal abscess \(severe\)](#) co-prescribed with [ampicillin Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribed with [benzylpenicillin Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [benzylpenicillin Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#)

**Second choice**

[Gonococcal infection](#) [Other specified prophylactic measures](#)

Other indications

[Bacterial infection of unspecified site](#)

**Glecaprevir + pibrentasvir** [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid: 50 mg + 20 mg granules
- Oral > Solid > tablet: 100 mg + 40 mg

Indications

[Chronic hepatitis C](#)

**Griseofulvin** [General information](#)

Section

Antifungal medicines

- Oral > Liquid: 125 mg per 5 mL
- Oral > Solid: 125 mg; 250 mg

Indications

[Dermatophytosis](#)

**Hydroxychloroquine** [General information](#)

Section

Antimalarial medicines > Medicines for chemoprevention

Indications

Therapeutic equivalent to [chloroquine](#) for [Malaria due to Plasmodium falciparum](#)

**Imipenem + cilastatin** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

Indications

**Second choice**

Therapeutic equivalent to [meropenem](#) for [Peritonitis \(severe\)](#) Therapeutic equivalent to [meropenem](#) for [Peritoneal abscess \(severe\)](#) Therapeutic equivalent to [meropenem](#) for [Neutropenia \(high-risk\)](#)

Other indications

[Pseudomonas aeruginosa resistant to other antibiotic](#) [Antibiotic resistant Acinetobacter baumannii](#)

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to [meropenem](#) for [Multi-drug resistant Mycobacterium tuberculosis](#)

**Imipenem + cilastatin + relebactam** [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection
- Parenteral > General injections > IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection

Indications

[Carbapenem resistant Enterobacterales](#) [Other specified other antibiotic resistant Enterobacterales](#) [Carbapenem-resistant Pseudomonas aeruginosa](#)

**Indinavir** [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 400 mg (as sulfate)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

**Isoniazid [General information](#)**

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 100 mg per mL
- Oral > Solid > dispersible tablet: 100 mg (scored)
- Oral > Solid > tablet: 100 mg; 300 mg

Indications

[Other specified tuberculosis Tuberculosis](#)

**Isoniazid + pyrazinamide + rifampicin [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg

Indications

[Tuberculosis](#)

**Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim [General information](#)**

Section

Medicines for prevention of HIV-related opportunistic infections

- Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)

Indications

[Other specified prophylactic measures](#)

**Isoniazid + rifampicin [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 50 mg + 75 mg
- Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg

Indications

[Tuberculosis](#)

**Isoniazid + rifapentine [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid: 300 mg + 300 mg tablet (scored)

Indications

[Latent tuberculosis](#)

**Itraconazole [General information](#)**

Section

Antifungal medicines

- Oral > Liquid: 10 mg per mL
- Oral > Solid: 100 mg

Indications

[Chronic pulmonary aspergillosis Chromoblastomycosis Histoplasmosis Talaromycosis Sporotrichosis Paracoccidioidomycosis](#)

**Ivermectin [General information](#)**

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 3 mg

Indications

[Strongyloidiasis Ascariasis Trichuriasis Ancylostomiasis Hookworm diseases](#)

Section

Medicines for ectoparasitic infections

- Oral > Solid > tablet: 3 mg

Indications

[Scabies](#)

Section

Antifilarials

- Oral > Solid > tablet: 3 mg

Indications

[Lymphatic filariasis Onchocerciasis](#)

#### **Kanamycin (injection) [General information](#)**

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

#### **Lamivudine [General information](#)**

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 150 mg tablet

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

#### **Lamivudine + nevirapine + zidovudine [General information](#)**

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

#### **Lamivudine + tenofovir [General information](#)**

Section

Fixed-dose combinations of antiretrovirals

Indications

Therapeutic equivalent to [emtricitabine + tenofovir](#) for [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#) Therapeutic equivalent to [emtricitabine + tenofovir](#) for [Contact with or exposure to human immunodeficiency virus](#)

#### **Lamivudine + zidovudine [General information](#)**

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

#### **Ledipasvir + sofosbuvir [General information](#)**

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 90 mg + 400 mg tablet

Indications

[Chronic hepatitis C](#)

#### **Levamisole [General information](#)**

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)

Indications

[Ascariasis](#)



#### **Levofloxacin** [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 250 mg; 500 mg; 750 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



#### **Linezolid** [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 400 mg tablet; 600 mg tablet
- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 600 mg

Indications

[Other specified bacterial diseases Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 150 mg (scored)
- Oral > Solid > tablet: 600 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



#### **Lopinavir + ritonavir** [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)
- Oral > Solid > dosage form: 40 mg + 10 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



#### **Mebendazole** [General information](#)

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)

Indications

[Ascariasis Enterobiasis Trichuriasis Hookworm diseases](#)

Section

Cysticidal medicines

- Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)

Indications

[Other specified echinococcosis](#)



#### **Mefloquine** [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid: 250 mg tablet (hydrochloride)

Indications

[Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax](#)

Section

Antimalarial medicines > Medicines for chemoprophylaxis in travellers

- Oral > Solid > tablet: 250 mg (scored) (as hydrochloride)

Indications

[Malaria due to Plasmodium falciparum](#)

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid: 250 mg tablet (hydrochloride)

Indications

[Malaria due to Plasmodium falciparum](#)

**Meglumine antimoniate** [General information](#)

Section

Antileishmaniasis medicines

- Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule

Indications

[Visceral leishmaniasis](#) [Mucocutaneous leishmaniasis](#) [Cutaneous leishmaniasis](#)

**Melarsoprol** [General information](#)

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

- Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)

Indications

[Gambiense trypanosomiasis](#) [Rhodesiense trypanosomiasis](#)

**Meropenem** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

**Second choice**

[Neonatal meningitis](#) [Peritonitis \(severe\)](#) [Peritoneal abscess \(severe\)](#) [Neutropenia \(high-risk\)](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

**Meropenem + vaborbactam** [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#) [Carbapenem resistant Acinetobacter baumannii](#)

**Meticillin** [General information](#)

Section

Access group antibiotics

Indications

**First choice**

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

**Second choice**

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

**Metronidazole** [General information](#)

Section

#### Access group antibiotics

- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Oral > Solid: 200 to 500 mg tablet
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
- Local > Rectal > Suppository: 500 mg; 1 g
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
- Oral > Solid > tablet: 500 mg; 200 mg; 250 mg; 400 mg

#### Indications

##### First choice

[Trichomoniasis](#) [Intestinal infections due to Clostridioides difficile](#) [Necrotising fasciitis](#) co-prescribed with [cefazolin](#) [Other specified prophylactic measures](#) co-prescribed with [cefotaxime](#) [Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [cefotaxime](#) [Peritoneal abscess \(severe\)](#) co-prescribed with [cefotaxime](#) [Peritonitis \(mild-moderate\)](#) co-prescribed with [cefotaxime](#) [Peritonitis \(severe\)](#) co-prescribed with [ceftriaxone](#) [Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [ceftriaxone](#) [Peritoneal abscess \(severe\)](#) co-prescribed with [ceftriaxone](#) [Peritonitis \(mild-moderate\)](#) co-prescribed with [ceftriaxone](#) [Peritonitis \(severe\)](#)

##### Second choice

co-prescribed with [ciprofloxacin](#) [Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [ciprofloxacin](#) [Peritonitis \(mild-moderate\)](#)

Other indications

[Bacterial infection of unspecified site](#)

#### Section

Antiamoebic and anti giardiasis medicines

- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Parenteral > General injections > unspecified: 500 mg in 100 mL vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

#### Indications

[Amoebiasis](#)

#### Micafungin [General information](#)

#### Section

Antifungal medicines

- Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection

#### Indications

[Systemic or invasive candidosis](#)

#### Miltefosine [General information](#)

#### Section

Antileishmaniasis medicines

- Oral > Solid: 10 mg; 50 mg

#### Indications

[Visceral leishmaniasis](#) [Cutaneous leishmaniasis](#) [Mucocutaneous leishmaniasis](#)

#### Moxidectin [General information](#)

#### Section

Antifilarials

- Oral > Solid > tablet: 2 mg

#### Indications

Therapeutic equivalent to [ivermectin](#) for [Lymphatic filariasis](#) Therapeutic equivalent to [ivermectin](#) for [Onchocerciasis](#)

#### Moxifloxacin [General information](#)

#### Section

Antituberculosis medicines

- Oral > Solid > tablet: 400 mg
- Oral > Solid > dispersible tablet: 100 mg

#### Indications

[Tuberculosis Multi-drug resistant Mycobacterium tuberculosis](#)

**Nafcillin** [General information](#)

Section  
Access group antibiotics  
Indications

**First choice**

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

**Second choice**

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

**Nalidixic acid** [General information](#)

Section  
Anti-infective medicines  
◦ Oral > Solid: 250 mg; 500 mg

Indications  
[Shigella resistant to unspecified antibiotic](#)

**Nelfinavir** [General information](#)

Section  
Antiretrovirals > Protease inhibitors  
◦ Oral > Solid: 250 mg (as mesilate)  
◦ Oral > Other: 50 mg per g oral powder

Indications  
[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

**Nevirapine** [General information](#)

Section  
Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors  
◦ Oral > Liquid: 50 mg per 5 mL  
◦ Oral > Solid > dispersible tablet: 50 mg  
◦ Oral > Solid > tablet: 200 mg

Indications  
[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

**Niclosamide** [General information](#)

Section  
Intestinal anthelmintics  
◦ Oral > Solid: 500 mg tablet (chewable)

Indications  
[Hymenolepiasis Diphyllbothriasis Taeniasis due to Taenia saginata Taeniasis due to Taenia solium](#)

**Nifurtimox** [General information](#)

Section  
American trypanosomiasis  
◦ Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)

Indications  
[Chagas disease](#)

Section  
Medicines for the treatment of 2nd stage African trypanosomiasis  
◦ Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)

Indications  
[Gambiense trypanosomiasis](#)

**Nitrofurantoin** [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL oral liquid
- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

**First choice**

[Infectious cystitis](#)

**Nystatin [General information](#)**

Section

Antifungal medicines

- Oral > Liquid: 100000 IU per mL
- Local > Topical > Other: 100000 IU pessary
- Oral > Solid > dosage form: 500000 IU
- Oral > Solid > lozenge: 100000 IU

Indications

[Candidosis](#)

**Ofloxacin [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid: 200 mg; 400 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

**Omadacycline [General information](#)**

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 100 mg lyophilized powder for injection
- Oral > Solid: 300 mg

Indications

[Methicillin resistant Staphylococcus aureus](#)

**Ombitasvir + paritaprevir + ritonavir [General information](#)**

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet

Indications

[Chronic hepatitis C](#)

**Oseltamivir [General information](#)**

Section

Other antivirals

- Oral > Liquid: 6 mg per mL (as phosphate) powder for oral liquid
- Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)

Indications

[Influenza due to identified seasonal influenza virus](#)

**Oxacillin [General information](#)**

Section

Access group antibiotics

Indications

**First choice**

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

**Second choice**

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

**Oxamniquine [General information](#)**

Section

Antischistosomes and other antitrematode medicines

- Oral > Liquid: 250 mg per 5 mL
- Oral > Solid > capsule: 250 mg

Indications

[Schistosomiasis due to Schistosoma mansoni](#)

**Oxazolindinones [General information](#)**

Section

Reserve group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

**P-aminosalicylate sodium [General information](#)**

Section

Antituberculosis medicines

- Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

**P-aminosalicylic acid [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid: 4 g granules in sachet

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

**Paromomycin [General information](#)**

Section

Antileishmaniasis medicines

- Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)

Indications

[Visceral leishmaniasis](#)

Section

Antiamoebic and anti-giardiasis medicines

- Oral > Liquid: 125 mg per 5 mL as sulfate
- Oral > Solid: 250 mg as sulfate

Indications

[Amoebiasis](#)

**Pegylated interferon alfa (2a) [General information](#)**

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

- Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

Indications

[Chronic hepatitis C](#)

**Pegylated interferon alfa (2b) [General information](#)**

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

- Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

Indications

[Chronic hepatitis C](#)

### **Pentamidine [General information](#)**

#### Section

Antileishmaniasis medicines

- Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)

Indications

[Visceral leishmaniasis](#)

#### Section

Medicines for the treatment of 1st stage African trypanosomiasis

- Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection

Indications

[Gambiense trypanosomiasis](#)

#### Section

Antipneumocystosis and antitoxoplasmosis medicines

- Oral > Solid > tablet: 200 mg (as isethionate); 300 mg (as isethionate)

Indications

[Pneumocystosis](#)

### **Phenoxyethylpenicillin [General information](#)**

#### Section

Access group antibiotics

- Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
- Oral > Solid: 250 mg (as potassium salt) tablet
- Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

Indications

**First choice**

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\) Periapical abscess without sinus Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)

### **Piperacillin + tazobactam [General information](#)**

#### Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

Indications

**First choice**

[Neutropenia \(high-risk\) Other specified pneumonia \(Hospital-acquired pneumonia\) Peritonitis \(severe\) Peritoneal abscess \(severe\)](#) co-prescribed with [clindamycin Necrotising fasciitis](#)

### **Plazomicin [General information](#)**

#### Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg per 10 mL

Indications

[Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales](#)

### **Polymyxin B (injection) [General information](#)**

#### Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

Indications

[Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii](#)

**Polymyxins [General information](#)**

Section

Reserve group antibiotics

◦ .

Indications

[Other specified bacterial diseases](#)

**Potassium iodide [General information](#)**

Section

Antifungal medicines

◦ Local > Topical > Solution: Saturated solution

Indications

[Sporotrichosis](#)

**Praziquantel [General information](#)**

Section

Cysticidal medicines

◦ Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Indications

[Cysticercosis of central nervous system](#)

Section

Antischistosomes and other antitrematode medicines

◦ Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Indications

[Paragonimiasis Clonorchiasis Opisthorchiasis Schistosomiasis](#)

Section

Intestinal anthelmintics

◦ Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Indications

[Diphyllobothriasis Taeniasis due to Taenia saginata Taeniasis due to Taenia solium Hymenolepiasis](#)

**Pretomanid [General information](#)**

Section

Antituberculosis medicines

◦ Oral > Solid > tablet: 200 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

**Primaquine [General information](#)**

Section

Antimalarial medicines > Medicines for curative treatment

◦ Oral > Solid > tablet: 7.5 mg (as phosphate); 15 mg (as phosphate)

Indications

[Malaria due to Plasmodium ovale Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax](#)

**Procaine benzylpenicillin [General information](#)**

Section

Access group antibiotics

◦ Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection

Indications

**First choice**

[Congenital syphilis \[children\]](#)

**Second choice**

[Syphilis](#)

**Proguanil** [General information](#)

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid: 100 mg tablet (hydrochloride)

Indications

[Malaria due to Plasmodium falciparum](#)

**Protionamide** [General information](#)

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to [ethionamide](#) for [Multi-drug resistant Mycobacterium tuberculosis](#)

**Pyrantel** [General information](#)

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)

Indications

[Ascariasis Enterobiasis Trichuriasis Hookworm diseases](#)

**Pyrazinamide** [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 400 mg; 500 mg

Indications

[Tuberculosis](#)

**Pyrimethamine** [General information](#)

Section

Antipneumocystosis and antitoxoplasmosis medicines

- Oral > Solid: 25 mg

Indications

[Toxoplasmosis](#)

**Quinine** [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion; 60 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion

Indications

[Malaria due to Plasmodium falciparum](#)

**Raltegravir** [General information](#)

Section

Antiretrovirals > Integrase inhibitors

- Oral > Liquid: 100 mg granules for oral suspension
- Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

**Ravidasvir** [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg

Indications

[Chronic hepatitis C](#)

### **Ribavirin [General information](#)**

#### Section

Medicines for hepatitis C > Other antivirals for hepatitis C

- Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
- Oral > Solid: 200 mg; 400 mg; 600 mg

#### Indications

[Chronic hepatitis C](#)

#### Section

Other antivirals

- Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
- Oral > Solid: 200 mg; 400 mg; 600 mg

#### Indications

[Viral haemorrhagic fever, not elsewhere classified](#)

### **Rifabutin [General information](#)**

#### Section

Antituberculosis medicines

- Oral > Solid: 150 mg

#### Indications

[Tuberculosis](#)

### **Rifampicin [General information](#)**

#### Section

Antituberculosis medicines

- Oral > Liquid: 20 mg per mL
- Oral > Solid: 150 mg; 300 mg
- Parenteral > General injections > IV: 600 mg in vial powder for injection

#### Indications

[Tuberculosis Other specified tuberculosis](#)

#### Section

Antileprosy medicines

- Oral > Liquid: 20 mg per mL
- Oral > Solid: 150 mg; 300 mg

#### Indications

[Leprosy](#)

### **Rifapentine [General information](#)**

#### Section

Antituberculosis medicines

- Oral > Solid > tablet: 150 mg; 300 mg
- Oral > Solid > dispersible tablet: 150 mg

#### Indications

[Tuberculosis Latent tuberculosis](#)

### **Ritonavir [General information](#)**

#### Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

#### Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

### **Saquinavir [General information](#)**

#### Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 200 mg; 500 mg

#### Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage](#)

[unspecified](#)



**Simeprevir** [General information](#)

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 150 mg

Indications

[Chronic hepatitis C](#)



**Sodium stibogluconate** [General information](#)

Section

Antileishmaniasis medicines

- Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial

Indications

[Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis](#)



**Sofosbuvir** [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg; 400 mg
- Oral > Solid > granules: 200 mg in sachet

Indications

[Chronic hepatitis C](#)



**Sofosbuvir + velpatasvir** [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg
- Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet

Indications

[Chronic hepatitis C](#)



**Spectinomycin** [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection

Indications

**Second choice**

[Gonococcal infection](#)

Other indications

[Bacterial infection of unspecified site](#)



**Stavudine** [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 5 mg per 5 mL powder for oral solution
- Oral > Solid: 15 mg; 20 mg; 30 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



**Streptomycin (injection)** [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial

Indications

## [Multi-drug resistant Mycobacterium tuberculosis](#)



### **Sulfadiazine** [General information](#)

#### Section

Antipneumocystosis and antitoxoplasmosis medicines

- Oral > Solid: 500 mg

#### Indications

[Toxoplasmosis](#)

#### Section

Anti-infective medicines

- Oral > Solid: 500 mg
- Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)

#### Indications

[Bacterial infection of unspecified site](#)



### **Sulfadimidine** [General information](#)

#### Section

Anti-infective medicines

- Oral > Liquid: 500 mg per 5 mL
- Oral > Solid: 500 mg
- Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)

#### Indications

[Bacterial infection of unspecified site](#)



### **Sulfadoxine + pyrimethamine** [General information](#)

#### Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid: 500 mg + 25 mg tablet
- Oral > Solid > dispersible tablet: 250 mg + 12.5 mg tablet

#### Indications

[Malaria due to Plasmodium falciparum Malaria](#)

#### Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid: 500 mg + 25 mg tablet

#### Indications

[Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax](#)



### **Sulfamethoxazole + trimethoprim** [General information](#)

#### Section

Access group antibiotics

- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
- Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
- Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
- Oral > Solid > dispersible tablet: 100 mg + 20 mg

#### Indications

#### First choice

[Infectious cystitis](#)

#### Second choice

[Infectious gastroenteritis or colitis without specification of infectious agent](#)

#### Other indications

[Bacterial infection of unspecified site](#)

#### Section

Antipneumocystosis and antitoxoplasmosis medicines

- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
- Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
- Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
- Oral > Solid > dispersible tablet: 100 mg + 20 mg

Indications

[Pneumocystosis](#)

**Suramin sodium [General information](#)**

Section

Antifilarials

- Parenteral > General injections > IV: 1 g in vial

Indications

[Filariasis](#)

Section

Medicines for the treatment of 1st stage African trypanosomiasis

- Parenteral > General injections > IV: 1 g in vial

Indications

[Rhodesiense trypanosomiasis](#)

**Tedizolid [General information](#)**

Section

Reserve group antibiotics

Indications

Therapeutic equivalent to [linezolid](#) for [Methicillin resistant Staphylococcus aureus](#) Therapeutic equivalent to [linezolid](#) for [Vancomycin resistant Staphylococcus aureus](#) Therapeutic equivalent to [linezolid](#) for [Vancomycin resistant Enterococcus](#)

**Tenofovir alafenamide [General information](#)**

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 25 mg

Indications

[Chronic hepatitis B](#)

**Tenofovir disoproxil fumarate [General information](#)**

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#) [Contact with or exposure to human immunodeficiency virus](#)

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

[Chronic hepatitis B](#)

**Terizidone [General information](#)**

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to [cycloserine](#) for [Multi-drug resistant Mycobacterium tuberculosis](#)

**Tetracycline [General information](#)**

Section

Access group antibiotics

- Oral > Solid: 250 mg (hydrochloride)

Indications

[Bacterial infection of unspecified site](#)

**Tigecycline [General information](#)**

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg in vial powder for injection

Indications

[Other specified bacterial diseases](#)

#### **Tinidazole** [General information](#)

Section

Antiamoebic and anti giardiasis medicines

Indications

Therapeutic equivalent to [metronidazole](#) for [Amoebiasis](#)

#### **Triclabendazole** [General information](#)

Section

Antischistosomes and other antitrematode medicines

- Oral > Solid > tablet: 250 mg (scored)

Indications

[Paragonimiasis](#) [Fascioliasis](#)

#### **Trimethoprim** [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 50 mg per mL
- Oral > Solid: 100 mg; 200 mg

Indications

**First choice**

[Infectious cystitis](#)

#### **Valganciclovir** [General information](#)

Section

Other antivirals

- Oral > Liquid: 50 mg per mL (as hydrochloride) powder for oral solution
- Oral > Solid > tablet: 450 mg (as hydrochloride)

Indications

[Cytomegaloviral retinitis](#)

#### **Vancomycin** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
- Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

Indications

**First choice**

[Necrotising fasciitis](#) co-prescribed with [ceftazidime](#) [Endophthalmitis](#) co-prescribed with [ceftriaxone](#) [Endophthalmitis](#)

**Second choice**

[Intestinal infections due to Clostridioides difficile](#) [Neutropenia \(high-risk\)](#)

Other indications

[Methicillin resistant Staphylococcus aureus](#)

#### **Voriconazole** [General information](#)

Section

#### Antifungal medicines

- Parenteral > General injections > IV: 200 mg in vial powder for injection
- Oral > Liquid: 40 mg per mL powder for oral liquid
- Oral > Solid: 50 mg tablet; 200 mg tablet

#### Indications

[Invasive aspergillosis](#) [Chronic pulmonary aspergillosis](#)



#### **Zidovudine** [General information](#)

#### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion
- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid > tablet: 300 mg
- Oral > Solid > capsule: 250 mg

#### Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)